Henrietta Lacks, HeLa Cells, and the Consent Problem in Tissue Research

The cells that became the HeLa line were taken from Henrietta Lacks's cervical tumor at Johns Hopkins in 1951 without her knowledge, and for decades neither she nor her family had any say in how they were used. That history still matters because it exposed a gap our ethics rules never fully closed: consent given for a single procedure cannot govern an immortal cell line, or a published genome that carries information about living relatives. The 2013 agreement between the National Institutes of Health and the Lacks family did not decide who owns the cells. It replaced one-time consent with ongoing governance, giving family members a seat on the committee that now reviews access to HeLa genome data.

What happened in 1951, and why it was legal

Henrietta Lacks was a 31-year-old Black woman treated for cervical cancer at Johns Hopkins Hospital in 1951. During her care, clinicians removed samples of her tumor and healthy tissue and passed them to the researcher George Gey, who found that her cells kept dividing in culture when other samples died within days. She was never told, and she died on 4 October 1951. Her family learned of the cells, by then shipped around the world, only in the 1970s.

None of that violated the rules of the era, which is the uncomfortable point. Informed consent for research did not yet exist as a legal requirement. The Nuremberg Code had been written in 1947, but the U.S. federal framework for human subjects, the Belmont Report and what became the Common Rule, arrived decades later. So the HeLa story is not only about one hospital. It is about how a practice that was ordinary at the time became indefensible once the science, and the cells, outlived the moment of consent.

Why a genome reopened the question

For sixty years the ethical debate centered on the tissue itself and on recognition for the family. In March 2013, a European research team sequenced and publicly posted the full HeLa genome, again without consulting the Lacks family. Genomic data differs from a tumor sample in one decisive way: a genome carries inherited information about a person's living relatives, including probabilistic signals about disease risk. Publishing Henrietta Lacks's genome effectively published data about her children and grandchildren. After public objection, the sequence was withdrawn.

That episode reframed the whole problem. The issue was no longer only what happened to one woman in 1951. It was that a cell line's genome is inherently relational, and that de-identification cannot protect a family whose name is attached to the most famous cells in biology.

What the NIH-Lacks agreement changed

On 7 August 2013, the NIH announced an agreement negotiated with the Lacks family. Writing in Nature, Kathy Hudson and NIH Director Francis Collins described the terms: HeLa whole-genome sequence data generated with NIH funding would be deposited in a controlled-access database, dbGaP, rather than posted openly. Researchers seeking the data must apply, and requests are reviewed by a HeLa Genome Data Access Working Group that includes two members of the Lacks family alongside scientists and bioethicists. Approved users agree to use the data only for biomedical research, to disclose commercial intentions, and to acknowledge the family in their publications.

A 2024 NIH notice (NOT-OD-24-098) folded these expectations into the agency's broader Data Management and Sharing Policy and kept the structure intact: deposit HeLa genome data to the designated controlled-access study, apply for access, and acknowledge Mrs. Henrietta Lacks and her family. The mechanism has now operated for more than a decade.

What changed conceptually is simple to state. Consent was reconceived as governance. Instead of a one-time yes or no, the family gained a continuing role in decisions about a specific, named dataset. That is a narrow fix. It applies only to NIH-funded HeLa genome data, not to the physical cells or to the thousands of HeLa lines already in circulation. But it modeled something an older consent form could not: a durable relationship between a research enterprise and the people a dataset can identify.

The ownership question it left open

The agreement deliberately sidestepped ownership, and it had to. U.S. law offers little support for the intuition that you own tissue once it leaves your body. In the 1990 case Moore v. Regents of the University of California, the state's supreme court held that a patient retained no property interest in cells that were removed and later commercialized. Governance, not property, was the only lever available.

That gap resurfaced in litigation. In 2021 the Lacks estate sued a laboratory-supply company, arguing it had been unjustly enriched by selling HeLa products, and the parties reached a confidential settlement in 2023, as reported by outlets including CNN and the Associated Press. A settlement is not a legal rule, and it does not establish that families own cell lines. It signals that the commercialization question the 2013 agreement set aside remains contested.

The lesson for tissue research now

The enduring lesson is that consent cannot be a single event when the material can be immortalized, sequenced, and shared indefinitely. Modern responses draw directly on this history: broad consent for future research, tiered data-access committees, benefit-sharing arrangements, and named acknowledgment of donors. None of these dissolves the tension between open science and the interests of identifiable people. They manage it, which is precisely what the NIH-Lacks arrangement does.

Henrietta Lacks's cells advanced work on the polio vaccine, cancer biology, and much of modern cell science. Honoring that contribution does not require pretending the consent was ever obtained. It requires building systems, as her family and the NIH eventually did, in which the people behind the samples keep a voice long after the sample is taken.